CASSIOPEIA: A phase 2 study evaluating efficacy and safety of tisagenlecleucel in first-line therapy for high-risk pediatric and young adult patients with B-ALL who are MRD positive at the EOC

被引：0
|
作者：
Maude, Shannon [1 ,2 ]
Stephen, Hunger [1 ,2 ]
Buechner, Jochen [3 ]
Grupp, Stephen [1 ,2 ]
Rives, Susana [4 ]
Baruchel, Andre [5 ,6 ]
Levine, John [7 ]
Krueger, Joerg [8 ]
Laetsch, Theodore [9 ]
Ifversen, Marianne [10 ]
Zia, Aiesha [11 ]
Davis, Jaclyn [12 ]
Bleickardt, Eric [12 ]
Loh, Mignon [13 ]
机构：
[1] Univ Penn, Philadelphia, PA 19104 USA
[2] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
[3] Oslo Univ Hosp, Oslo, Norway
[4] St Joan de Deu Hosp, Barcelona, Spain
[5] Hop Robert Debre, Paris, France
[6] Univ Paris, Paris, France
[7] Mt Sinai Sch Med, New York, NY USA
[8] Hosp Sick Children, Toranto, ON, Canada
[9] UT Southwestern Med Ctr & Child, Dallas, TX USA
[10] Rigshospi, Copenhagen Univ Hosp, Copenhagen, Denmark
[11] Novartis Pharma AG, Basel, Switzerland
[12] Novartis Pharmaceut, E Hanover, NJ USA
[13] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2019年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P405
引用
收藏
页数：2
相关论文
共 50 条
  • [1] CASSIOPEIA: A phase 2 study evaluating efficacy and safety of tisagenlecleucel in first-line therapy for high-risk pediatric and young adult patients with B-cell Acute Lymphoblastic Leukemia (B-ALL) who are MRD positive at the End of Consolidation (EOC)
    Buechner, J.
    Rives, S.
    Maude, S.
    Hunger, S.
    Grupp, S.
    Levine, J.
    Feuchtinger, T.
    Zia, A.
    Davis, J.
    Pacaud, L.
    Deore, U.
    Loh, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 36 - 36
  • [2] HESTER: A Phase II Study Evaluating Efficacy and Safety of Tisagenlecleucel Reinfusion in Pediatric and Young Adult Patients with Acute Lymphoblastic Leukemia Experiencing Loss of B-Cell Aplasia
    Boyer, Michael W.
    Chaudhury, Sonali
    Davis, Kara L.
    Driscoll, Timothy Alan
    Grupp, Stephan A.
    Hermiston, Michelle
    John, Samuel
    Keating, Amy K.
    Kovacs, Christina
    Magley, Andrea
    Myers, Gary Douglas
    Phillips, Christine L.
    Pulsipher, Michael A.
    Purkayastha, Das
    Talano, Julie-An
    Willert, Jennifer
    BLOOD, 2020, 136
  • [3] Evaluating Efficacy and Safety of Tisagenlecleucel Reinfusion Following Loss of B-Cell Aplasia in Pediatric and Young Adult Patients with Acute Lymphoblastic Leukemia: HESTER Phase II Study
    Boyer, Michael W.
    Chaudhury, Sonali
    Davis, Kara L.
    Driscoll, Timothy Alan
    Grupp, Stephan A.
    Hermiston, Michelle
    John, Samuel
    Keating, Amy K.
    Kovacs, Christina
    Myers, G. Doug
    Phillips, Christine L.
    Pulsipher, Michael A.
    Talano, Julie-An
    Kari, Gabor
    Willert, Jennifer
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S262 - S263
  • [4] ZUMA-12: A Phase 2 Multicenter Study of Axicabtagene Ciloleucel as a First-Line Therapy in Patients With High-Risk Large B Cell Lymphoma
    Neelapu, Sattva S.
    Chavez, Julio C.
    Lin, Yi
    Munoz, Javier
    Ujjani, Chaitra S.
    Riedell, Peter
    De Vos, Sven
    Oluwole, Olalekan O.
    Kekre, Natasha
    Yang, Yin
    Goyal, Lovely
    Backhouse, Kate
    Milletti, Francesca
    Kawashima, Jun
    Herrera, Alex F.
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 : S19 - S19
  • [5] Interim analysis of ZUMA-12: a phase 2 study of axicabtagene ciloleucel as first-line therapy in patients with high-risk large B-cell lymphoma
    Neelapu, Sattva S.
    Dickinson, Michael
    Munoz, Javier
    Ulrickson, Matthew L.
    Oluwole, Olalekan O.
    Herrera, Alex F.
    Thieblemont, Catherine
    Ujjani, Chaitra S.
    Lin, Yi
    Riedell, Peter A.
    Kekre, Natasha
    De Vos, Sven
    Yang, Yin
    Milletti, Francesca
    Goyal, Lovely
    Kawashima, Jun
    Chavez, Julio C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 36 - 37
  • [6] Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel as First-Line Therapy in Patients With High-Risk Large B-Cell Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (03) : 16 - 18
  • [7] Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial
    Sattva S. Neelapu
    Michael Dickinson
    Javier Munoz
    Matthew L. Ulrickson
    Catherine Thieblemont
    Olalekan O. Oluwole
    Alex F. Herrera
    Chaitra S. Ujjani
    Yi Lin
    Peter A. Riedell
    Natasha Kekre
    Sven de Vos
    Christine Lui
    Francesca Milletti
    Jinghui Dong
    Hairong Xu
    Julio C. Chavez
    Nature Medicine, 2022, 28 : 735 - 742
  • [8] Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial
    Neelapu, Sattva S.
    Dickinson, Michael
    Munoz, Javier
    Ulrickson, Matthew L.
    Thieblemont, Catherine
    Oluwole, Olalekan O.
    Herrera, Alex F.
    Ujjani, Chaitra S.
    Lin, Yi
    Riedell, Peter A.
    Kekre, Natasha
    de Vos, Sven
    Lui, Christine
    Milletti, Francesca
    Dong, Jinghui
    Xu, Hairong
    Chavez, Julio C.
    NATURE MEDICINE, 2022, 28 (04) : 735 - +
  • [9] A Double-Blind, Randomized, Placebo-Controlled, Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib in Combination with Paclitaxel as a First-Line Therapy in Patients with Locally Recurrent or Metastatic Breast Cancer
    Gradishar, W. J.
    Kaklamani, V
    Sahoo, Prasad T.
    Lokanatha, D.
    Raina, V
    Bondarde, S.
    Jain, M.
    CANCER RESEARCH, 2009, 69 (24) : 496S - 496S
  • [10] Primary Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL)
    Neelapu, Sattva S.
    Dickinson, Michael
    Munoz, Javier
    Ulrickson, Matthew L.
    Thieblemont, Catherine
    Oluwole, Olalekan O.
    Herrera, Alex F.
    Ujjani, Chaitra S.
    Lin, Yi
    Riedell, Peter A.
    Kekre, Natasha
    de Vos, Sven
    Lui, Christine
    Milletti, Francesca
    Dong, Jinghui
    Xu, Hairong
    Chavez, Julio C.
    BLOOD, 2021, 138
12345